每周一次大分割全乳照射治疗早期乳腺癌的2期试验最终分析
PURPOSE: We hypothesize that 5-fraction once weekly hypofractionated (WH) whole breast irradiation (WBI) would be safe and effective after breast-conserving surgery for medically underserved patients with breast cancer.…
要点
- 每周一次大分割全乳照射5年同侧乳腺肿瘤复发率为2.7%(95%CI 0.89-6.34)。
- 5年无远处疾病生存率96.4%,无复发生存率95.8%,总生存率96.7%。
- 导管原位癌、小叶组织学、低级别、T1、Her2阴性及接受瘤床加量者无复发生存时间改善。
核心结论
- 术后每周一次大分割全乳照射具有较好的疾病特异结局,与传统及中度大分割放疗技术所见相当。
- 该方案可改善医疗资源不足的0-II期乳腺癌患者的就医可及性。
研究设计与样本
- 2期前瞻性机构审查委员会批准方案研究,纳入保乳术后切缘阴性且符合预设医疗资源不足标准的0-II期乳腺癌女性。
- 全乳照射28.5或30 Gy,不 elective 覆盖淋巴结,主要终点为5年同侧乳腺肿瘤复发。
主要发现
- 分期分布:22%导管原位癌,68%浸润性pN0,10%浸润性pN1;28%患者为3级肿瘤,10%雌激素受体阴性,24%需辅助化疗。
- 共6例同侧乳腺肿瘤复发事件,5年、7年、10年复发风险分别为2.7%(95%CI 0.89-6.34)、4.7%(95%CI 1.4-11.0)、7.2%(95%CI 2.4-15.8)。
- 5年、7年、10年无远处疾病生存率分别为96.4%、96.4%、86.4%;无复发生存率分别为95.8%、93.6%、80.7%;总生存率分别为96.7%、88.6%、76.7%。
- 导管原位癌、小叶组织学、低级别肿瘤、T1期、Her2阴性肿瘤及接受瘤床加量者无复发生存时间改善。
临床怎么用
- 对于医疗资源不足的0-II期乳腺癌保乳术后患者,可考虑每周一次5次大分割全乳照射(28.5或30 Gy)作为治疗选择。
- 治疗决策时可参考导管原位癌、小叶组织学、低级别、T1、Her2阴性及瘤床加量等与无复发生存改善相关的因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We hypothesize that 5-fraction once weekly hypofractionated (WH) whole breast irradiation (WBI) would be safe and effective after breast-conserving surgery for medically underserved patients with breast cancer. We report the protocol-specified primary endpoint of in-breast tumor recurrence (IBTR) at 5 years. METHODS AND MATERIALS: After provided informed consent, patients were treated with WH-WBI after breast-conserving surgery were followed prospectively on an institutional review board-approved protocol. Women included in this study had stage 0-II breast cancer treated with negative surgical margins and met prespecified criteria for being underserved. WH-WBI was 28.5 or 30 Gy delivered to the whole breast with no elective coverage of lymph nodes. The primary endpoint was IBTR at 5 years. Secondary endpoints were distant disease-free survival, recurrence-free survival, overall survival, adverse events, and cosmesis. RESULTS: One hundred fifty-eight patients received WH-WBI on protocol from 2010 to 2015. Median follow-up was 5.5 years (range, 0.2-10.0 years). Stage distribution was 22% ductal carcinoma in situ, 68% invasive pN0, and 10% invasive pN1. Twenty-eight percent of patients had grade 3 tumors, 10% were estrogen receptor negative, and 24% required adjuvant chemotherapy. There were 6 IBTR events. The 5-, 7-, and 10-year risks of IBTR for all patients were 2.7% (95% confidence interval [CI], 0.89-6.34), 4.7% (95% CI, 1.4-11.0) and 7.2% (95% CI, 2.4-15.8), respectively. The 5-, 7-, and 10-year rates of distant disease-free survival were 96.4%, 96.4%, and 86.4%; the recurrence-free survival rates were 95.8%, 93.6%, and 80.7%; and the overall survival rates were 96.7%, 88.6%, and 76.7%, respectively. Improvement in IBTR-free time was seen in ductal carcinoma in situ, lobular histology, low-grade tumors, T1 stage, Her2-negative tumors, and receipt of a radiation boost to the lumpectomy bed. CONCLUSIONS: Postoperative WH-WBI has favorable disease-specific outcomes that are comparable to those seen with conventional and moderately hypofractionated radiation techniques. WH-WBI could improve access to care for underserved patients with stage 0-II breast cancer.
引用
- Reshko LB, Pan J, Rai SN, et al. Final Analysis of a Phase 2 Trial of Once Weekly Hypofractionated Whole Breast Irradiation for Early-Stage Breast Cancer. Int J Radiat Oncol Biol Phys. 2021. PMID: 34710520. doi:10.1016/j.ijrobp.2021.06.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。